Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Total Revenue of $30.77 million for fiscal year 2017.
HERON THERAPEUTICS, INC. /DE/ — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$20.20M -48.7% |
-$13.58M +87.7% |
-$110.56M +39.3% |
-$182.02M +17.5% |
-$220.68M +2.9% |
-$227.28M -11.0% |
| Diluted EPS | -$0.12 -33.3% |
-$0.09 +88.8% |
-$0.80 +52.1% |
-$1.67 +25.4% |
-$2.24 | — |
| Total Assets | $255.88M +9.7% |
$233.15M +4.8% |
$222.51M -11.3% |
$250.95M -17.9% |
$305.71M -13.5% |
$353.56M -31.1% |
| Cash and Equivalents | $28.65M +11.0% |
$25.80M -10.0% |
$28.68M +86.7% |
$15.36M -83.0% |
$90.54M -13.9% |
$105.14M +46.2% |
| Stockholders Equity | $14.33M +142.6% |
-$33.65M +0.9% |
-$33.97M -350.3% |
$13.57M -82.5% |
$77.57M -67.2% |
$236.49M -41.4% |
| R&D Expense | $12.43M -25.5% |
$16.68M -57.4% |
$39.13M -52.7% |
$82.70M -36.8% |
$130.82M -25.0% |
$174.53M +4.3% |
| Operating Income | -$2.54M +78.0% |
-$11.53M +89.6% |
-$110.61M +36.7% |
-$174.66M +19.8% |
-$217.83M +4.5% |
-$228.16M -8.3% |
| Gross Profit | $113.56M +7.5% |
$105.64M +70.6% |
$61.94M +17.3% |
$52.80M | — | — |
| Shares Outstanding | 188.31M +23.8% |
152.13M +1.2% |
150.29M +26.1% |
119.15M +16.8% |
102.00M +11.7% |
91.31M +1.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $8.57M | — | +0.7% |
| Net Income | September 30, 2025 | -$17.50M | -260.9% | -634.8% |
| Diluted EPS | September 30, 2025 | -$0.10 | -233.3% | -400.0% |
| Total Assets | September 30, 2025 | $248.95M | +12.8% | +7.3% |
| Cash and Equivalents | September 30, 2025 | $43.07M | +67.3% | +160.8% |
| Stockholders Equity | September 30, 2025 | $14.88M | +137.2% | +154.6% |
| R&D Expense | September 30, 2025 | $3.47M | -22.3% | +18.3% |
| Operating Income | September 30, 2025 | -$4.09M | +8.2% | -150.0% |
| Gross Profit | September 30, 2025 | $26.30M | +12.6% | -3.8% |
- HERON THERAPEUTICS, INC. /DE/ reported Total Revenue of $30.77 million for fiscal year 2017.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +2305.6% in Total Revenue compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Net Income of -$20.20 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -48.7% in Net Income compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -33.3% in Diluted EPS compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Total Assets of $255.88 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +9.7% in Total Assets compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Cash and Equivalents of $28.65 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +11.0% in Cash and Equivalents compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Stockholders Equity of $14.33 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +142.6% in Stockholders Equity compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported R&D Expense of $12.43 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -25.5% in R&D Expense compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Operating Income of -$2.54 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +78.0% in Operating Income compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Gross Profit of $113.56 million for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +7.5% in Gross Profit compared to the prior fiscal year.
- HERON THERAPEUTICS, INC. /DE/ reported Shares Outstanding of 188.31 million shares for fiscal year 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +23.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: